Evidence mapPaperPMID 30226564Full record

ArticleInternational journal of molecular medicine2018

Upregulation of miR-183-5p is responsible for the promotion of apoptosis and inhibition of the epithelial-mesenchymal transition, proliferation, invasion and migration of human endometrial cancer cells by downregulating Ezrin.

Hua Yan, Bing-Mei Sun, Yu-Ying Zhang, Yu-Juan Li, Cheng-Xiang Huang, Fu-Zhong Feng, Cui Li

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Advances in MiRNAs Involved in Endometrial Carcinoma.Combinatorial chemistry & high throughput screening · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. MicroRNAs and Heat Shock Proteins in Breast Cancer Biology.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  12. Article
  13. Review
  14. Article
  15. Non-Coding RNAs as Prognostic Markers for Endometrial Cancer.International journal of molecular sciences · 2021
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hua YanDepartment of Obstetrics and Gynecology, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China.
Bing-Mei SunDepartment of Obstetrics and Gynecology, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China.
Yu-Ying ZhangDepartment of Obstetrics and Gynecology, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China.
Yu-Juan LiDepartment of Obstetrics and Gynecology, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China.
Cheng-Xiang HuangDepartment of Obstetrics and Gynecology, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China.
Fu-Zhong FengDepartment of Obstetrics and Gynecology, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China.
Cui LiDepartment of Obstetrics and Gynecology, Linyi Central Hospital, Linyi, Shandong 276400, P.R. China.
Linyi People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer is a life‑threatening malignancy that affects women all over the world, and it has an increasing incidence. MicroRNAs (miRNAs/miRs) have been reported to be involved in cellular activities in endometrial cancer. The present study aimed to examine the effects of miR‑183‑5p on the epithelial‑mesenchymal transition (EMT), proliferation, invasion, migration and apoptosis of human endometrial cancer cells by targeting Ezrin. Primary endometrial cancer tissues and adjacent normal tissues were obtained for the investigation. The protein expression of Ezrin in tissues was detected by immunohistochemistry. The expression level of miR‑183‑5p and the mRNA and protein expression levels of Ezrin and EMT‑associated genes were determined by reverse transcription‑quantitative polymerase chain reaction and western blot analyses. Endometrial cancer cells were treated with miR‑183‑5p inhibitors, small interfering RNA targeting Ezrin or miR‑183‑5p inhibitors. Cell proliferation, cell cycle, apoptosis, migration and invasion were then evaluated using an MTT assay, flow cytometry, scratch test and Transwell assay, respectively. Compared with normal adjacent tissues, the expression of miR‑183‑5p was decreased in endometrial cancer tissues, and the expression of Ezrin was significantly increased in endometrial cancer tissues. The protein expression of Ezrin was correlated with the severity and poor prognosis of endometrial cancer. Notably, the target prediction program and the luciferase reporter gene assay confirmed that miR‑183‑5p targeted and negatively regulated the expression of Ezrin. In vivo experiments revealed that the increased expression of miR‑183‑5p and decreased expression of Ezrin inhibited EMT, cell proliferation, migration and invasion, but promoted cell apoptosis in Ishikawa cells. These results suggested that the upregulated expression of miR‑183‑5p promoted apoptosis and suppressed the EMT, proliferation, invasion and migration of human endometrial cancer cells by downregulating Ezrin.

Indexed as

Epithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticAdultApoptosisCell Line, TumorCell MovementCell ProliferationCytoskeletal ProteinsDown-RegulationEndometrial NeoplasmsEzrinFemaleHumansMicroRNAsMiddle AgedNeoplasm InvasivenessCytoskeletal ProteinsEzrinMicroRNAsMIRN183 microRNA, human

Identifiers

PMID30226564
PMCPMC6192766
OpenAlexW2890544808

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.